Esperion Therapeutics (NASDAQ:ESPR) Acquisition by ARCHIMED: Key Details and Shareholder Concerns

Font: Financial Modeling Prep  • May 01, 2026

• Esperion Therapeutics (NASDAQ:ESPR), a biopharmaceutical company, is being acquired by healthcare investment firm ARCHIMED for up to $1.1 billion, taking the company private.
• Shareholders are set to receive $3.16 per share in cash, along with potential contingent milestone payments of up to $100 million, which led to a stock price surge of over 55%.
• The acquisition deal faces an investigation by Halper Sadeh LLC, scrutinizing the fairness of the sales process and whether Esperion's board secured the best possible shareholder value.

Esperion Therapeutics (NASDAQ:ESPR) is a biopharmaceutical company that develops and commercializes innovative medicines for managing cholesterol. The company is currently being acquired by the specialized healthcare investment firm ARCHIMED in a significant acquisition deal that will take it private. This means that ESPR shares will no longer trade on the public stock exchange, marking a pivotal moment for the company and its investors.

As highlighted by GlobeNewswire, this strategic acquisition has a total equity value of up to $1.1 billion. Under the terms of the agreement, Esperion Therapeutics shareholders are set to receive $3.16 per share in cash. Additionally, they will also receive a right to potential future payments, known as contingent milestone payments, which could amount to an additional $100 million, tied to future performance metrics.

Following the announcement of the acquisition news, Esperion's stock price surged over 55% to $3.11, trading very close to the offer price. The stock experienced a massive trading volume of over 180.9 million shares, indicating high investor activity and strong market interest. This significant price movement clearly reflects the market's immediate reaction to the value established by the acquisition agreement.

On the same day, May 1, 2026, prominent analyst firm Jefferies (NYSE: JEF) downgraded its rating on Esperion to 'Hold' when the stock was trading at $3.11. A 'Hold' rating typically signifies that an analyst believes the stock will perform in line with the broader market, suggesting limited potential for significant gains or losses from its current price point, reflecting a neutral outlook on its future market performance.

However, the acquisition deal is currently facing an investigation from the law firm Halper Sadeh LLC, as reported by Business Wire. The firm is meticulously examining whether Esperion's board of directors failed to secure the best possible price for its shareholders. The investigation specifically questions the fairness of the entire sales process and whether all important information pertinent to the deal was fully and transparently disclosed to investors, raising concerns about shareholder value.